Capolongo L, Melegaro G, Broggini M, Mongelli N, Grandi M
Farmitalia Carlo Erba, Research Center, Oncology Department, Nerviano, Milano, Italy.
Br J Cancer. 1993 Nov;68(5):916-9. doi: 10.1038/bjc.1993.454.
Human colon adenocarcinoma cells (LoVo) resistant to the new antitumor agent FCE 24517 [benzoyl-mustard derivative of distamycin A] (LoVo/24517) are resistant to the selecting agent and related molecules as well as to vinblastine, with marginal or no resistance to other antitumour drugs. Treatment with verapamil, tamoxifen, nicergoline or cyclosporin A only partially restores the activity of FCE 24517 against LoVo/24517 cells. Such results suggest that resistance mechanisms possible specific for this class of compounds are operating.
对新型抗肿瘤药物FCE 24517[放线菌素A的苯甲酰-氮芥衍生物]具有抗性的人结肠腺癌细胞(LoVo)(LoVo/24517),对选择剂及相关分子以及长春碱具有抗性,对其他抗肿瘤药物仅有轻微抗性或无抗性。用维拉帕米、他莫昔芬、尼麦角林或环孢素A处理只能部分恢复FCE 24517对LoVo/24517细胞的活性。这些结果表明,可能存在针对这类化合物的特异性抗性机制在起作用。